Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
Business Wire•23/09/2026•16:01 ET
0
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing Phase 2 study
Get started
Create a free account to read the full story and Whiz Insights.